Aspirin, Clopidogrel

Pre-clinicalCompleted
0 watching 0 views this week๐Ÿ’ค Quiet
23
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Ischemic Stroke

Conditions

Ischemic Stroke

Trial Timeline

Apr 1, 2019 โ†’ Jan 3, 2022

About Aspirin, Clopidogrel

Aspirin, Clopidogrel is a pre-clinical stage product being developed by Yuhan for Ischemic Stroke. The current trial status is completed. This product is registered under clinical trial identifier NCT03823274. Target conditions include Ischemic Stroke.

Hype Score Breakdown

Clinical
5
Activity
2
Company
10
Novelty
2
Community
1

Clinical Trials (1)

NCT IDPhaseStatus
NCT03823274Pre-clinicalCompleted

Competing Products

20 competing products in Ischemic Stroke

See all competitors
ProductCompanyStageHype Score
DS-1040b + PlaceboDaiichi SankyoPhase 1/2
41
DS-1040b + AspirinDaiichi SankyoPhase 1
33
DS1040b + PlaceboDaiichi SankyoPre-clinical
23
Pharmacological intensification based on olmesartanDaiichi SankyoPhase 2
52
RegadenosonAstellas PharmaPhase 1
33
YM872 (zonampanel), t-PA (alteplase)Astellas PharmaPhase 2
52
RegadenosonAstellas PharmaApproved
85
ASP2246Astellas PharmaPhase 1/2
41
Gadolinium + AdenosineAstellas PharmaPhase 2/3
65
XY03-EA + XY03-EA PlaceboSun PharmaceuticalPhase 2
52
Redasemtide + PlaceboShionogiPhase 2
52
StatinShionogiApproved
85
fospropofol + propofolEisaiPhase 2
52
PDE5 InhibitorsEli LillyPre-clinical
23
SB623 Implant (2.5M) + SB623 Implant (5.0M)Sumitomo PharmaPhase 2
52
Mesenchymal stem cell + PlaceboRohto PharmaceuticalPhase 2
52
Elezanumab + PlaceboAbbViePhase 2
52
Balovaptan + PlaceboRochePhase 2
52
RepathaAmgenApproved
84
GS-6615 + PlaceboGilead SciencesPhase 1
32